This web publication constitutes a notice for the purposes of regulation 42ZCZS and regulation 42ZCZX of the Therapeutic Goods Regulations 1990 (the Regulations). In accordance with regulations 42ZCZS and 42ZCZX, this notice publishes:
- the decisions made by a delegate of the Secretary pursuant to regulations 42ZCZR and 42ZCZU;
- the reasons for those final decisions; and
- the date of effect of those decisions.
Contents
- 1 Final decisions made pursuant to regulation 42ZCZR – proposals referred to the November 2019 Advisory Committee on Medicines Schedule (ACMS #28)
- 1.1. Final decision in relation to Sumatripan
- 1.2. Final decision in relation to Zolmitriptan
- 1.3. Final decision in relation to Mometasone
- 1.4. Final decision in relation to calcifediol monohydrate
- 1.5. Final decision in relation to Paracetamol (liquid formulations)
- 1.6. Final decision in relation to Paracetamol + ibuprofen
- 1.7. Final decision in relation to Hyoscine butylbromide
- 1.8. Final decision in relation to Lidocaine
- 2 Final decisions made pursuant to regulation 42ZCZR – proposals referred to the November 2019 Joint Advisory Committee on Medicines and Chemicals Scheduling (ACCS-ACMS #23)
- 3 Final decisions made pursuant to regulation 42ZCZR – proposals referred to the November 2019 Advisory Committee on Chemicals Scheduling (ACCS #26)
- 4 Final decision(s) (without interim decision) made pursuant to regulation 42ZCZU
- 5 Notice of an amendment to the current Poisons Standard in relation to Modified-release (MR) paracetamol